Bacterial Keratitis Clinical Trial
This study evaluates the safety and efficacy of gatifloxacin 0.3% ophthalmic solution compared with ciprofloxacin 0.3% ophthalmic solution in patients with acute bacterial corneal ulcers
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02497365 -
Besifloxacin in Bacterial Keratitis
|
N/A | |
Terminated |
NCT02088970 -
Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL)
|
N/A | |
Recruiting |
NCT03918408 -
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions
|
Phase 1 | |
Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
Recruiting |
NCT02016989 -
Matrix Therapy And Bacterial Keratitis
|
N/A | |
Completed |
NCT00386958 -
A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers
|
Phase 2 | |
Recruiting |
NCT04213885 -
Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position
|
Phase 2 | |
Completed |
NCT01831206 -
Collagen Cross-linking in Infectious Keratitis Trial
|
Phase 2 | |
Completed |
NCT03845374 -
Prospective, Randomized Multi-Center Study of Using the Hyper-CLâ„¢ Lens in Subjects Suffering From Bacterial Keratitis
|
N/A | |
Completed |
NCT00707005 -
Antibiotic Susceptibility of Conjunctival Bacterial Isolates From Refractive Surgery Patients
|
N/A | |
Completed |
NCT05655689 -
The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study
|
||
Not yet recruiting |
NCT06271772 -
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II
|
Phase 3 |